Anti-FLT4 Antibody

Cat: 10806-MM03
Contact us:
All FLT4 Reagents
CRO Services
Product recommended

All FLT4 Reagents
Anti-FLT4 Antibody (Mouse Monoclonal antibody) General Information
Product name
Anti-FLT4 Antibody
Validated applications
Species reactivity
Reacts with: Human
Human FLT4
Recombinant Human VEGFR3 protein (Catalog#10806-H08H)
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human VEGFR3 extracellular domain (rhVEGFR3; Catalog#10806-H08H; aa 1-776; NP_002011.2). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Monoclonal Mouse IgG1 Clone #2B2F12C5
Protein A
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Anti-FLT4 Antibody (Mouse Monoclonal antibody) Validated Applications
Application Dilution Notes
ELISA 1:1000-1:2000  

**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********

Anti-FLT4 Antibody Alternative Names
Anti-FLT-4 Antibody;Anti-FLT-41 Antibody;Anti-FLT41 Antibody;Anti-LMPH1A Antibody;Anti-PCL Antibody;Anti-VEGF Receptor 3 Antibody;Anti-VEGFR-3 Antibody;Anti-VEGFR3 Antibody
FLT4 Background Information

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Full Name
fms related tyrosine kinase 4
  • Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52.
  • Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36.
  • Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5.
  • Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.
  • Product Description Host Clonality Application Catalog# (PDF)
    Anti-FLT4 Antibody Rabbit Monoclonal ELISA 50584-R002
    Anti-FLT4 Antibody Rabbit Polyclonal ELISA 50584-RP02
    Anti-FLT4 Antibody Mouse Monoclonal ELISA(Cap) 10806-MM02
    Anti-FLT4 Antibody Rabbit Monoclonal ELISA 10806-R005
    Anti-FLT4 Antibody Mouse Monoclonal ELISA(Det) 10806-MM06
    Anti-FLT4 Antibody Rabbit Polyclonal ELISA 10806-RP01
    Anti-FLT4 Antibody Rabbit Polyclonal WB,ELISA 10806-RP04
    Anti-FLT4 Antibody Rabbit Polyclonal ELISA 10806-T16
    info info
    添加购物车成功! 添加购物车失败!